Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | MAOB | P27338 | 5/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.55 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.55 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.53 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.53 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.53 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.53 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MMP1 | P03956 | 2/20 | 0.50 |
| ▸ | MMP2 | P08253 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8464563 | 1.00 | CYP1A2 (0.67) | CYP1A2MAOBHDAC2CYP1B1CXCL12 | |
| SCHEMBL1620259 | 1.00 | CYP1A2 (0.67) | CYP1A2MAOBHDAC2CYP1B1CXCL12 | |
| SCHEMBL27685617 | 0.98 | CYP1A2 (0.64) | CYP1A2MAOBHDAC2CYP1B1CXCL12 | |
| SCHEMBL28347012 | 0.89 | CYP1A2 (0.75) | CYP1A2MAOBHDAC2CYP1B1CXCL12 | |
| SCHEMBL126171 | 0.83 | CYP1A2 (0.72) | CYP1A2MAOBHDAC2CYP1B1CXCL12 | |
| SCHEMBL269140 | 0.83 | CYP1A2 (0.72) | CYP1A2MAOBHDAC2CYP1B1CXCL12 | |
| SCHEMBL4732055 | 0.83 | CYP1A2 (0.72) | CYP1A2MAOBHDAC2CYP1B1CXCL12 | |
| SCHEMBL11452510 | 0.81 | CYP1A2 (0.69) | CYP1A2MAOBHDAC2CYP1B1CXCL12 | |
| Hydrochloric Acid SCHEMBL27093050 | 0.81 | CYP1A2 (0.69) | CYP1A2MAOBHDAC2CYP1B1CXCL12 | |
| Hydrochloric Acid SCHEMBL5929339 | 0.81 | CYP1A2 (0.69) | CYP1A2MAOBHDAC2CYP1B1CXCL12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120040348-A | Preparation method for efficiently synthesizing CB1 antagonist pyrazole derivative | 中国药科大学 | 2025-05-27 | — | — | CN | disclosed |
| US-20140273130-A1 | COMPETITIVE GROWTH AND/OR PRODUCTION ADVANTAGE FOR BUTANOLOGEN MICROORGANISM | BUTAMAX ADVANCED BIOFUELS LLC (US) | 2014-09-18 | — | — | US | disclosed |
| EP-1626963-B1 | Substituted pyrazoline compounds, their preparation and use as medicaments | ESTEVE LABOR DR (ES) | 2012-08-15 | — | — | EP | disclosed |
| US-8207156-B2 | Substituted pyrazoline compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-06-26 | — | — | US | disclosed |
| EP-1910299-B1 | SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2011-09-07 | — | — | EP | disclosed |
| US-7998996-B2 | Controlling triglyceride concentration; central nervous system disorders; psychological disorders; eating disordes; drug abuse; anticancer agents | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2011-08-16 | — | — | US | disclosed |
| US-20110160459-A1 | 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLINES AS CANNABINOID CB1 RECEPTOR AGONISTS | SOLVAY PHARMACEUTICALS, B.V. | 2011-06-30 | — | — | US | disclosed |
| US-20110160181-A1 | SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-06-30 | — | — | US | disclosed |
| US-7968582-B2 | 5(S)-substituted pyrazoline compounds, their preparation and use as medicaments | LABOROTORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-06-28 | — | — | US | disclosed |
| US-7928134-B2 | 5-aryl-4,5-dihydro-(1H)-pyrazolines as cannabinoid CB1 receptor agonists | SOLVAY PHARMACEUTICALS B.V. (NL) | 2011-04-19 | — | — | US | disclosed |
| EP-1718619-A1 | SUBSTITUTED PYRAZOLINE COMPOUNDS FOR REDUCING TRIGLYCERIDES IN BLOOD | Laboratorios del Dr. Esteve S.A. (ES) | 2006-11-08 | — | — | EP | disclosed |
| US-20060189658-A1 | Substituted pyrazoline compounds, their preparation and use as medicaments | LABORATORIOS DR. ESTEVE S.A. (ES) | 2006-08-24 | — | — | US | disclosed |
| EP-1637522-A1 | Substituted pyrazoline compounds for reducing triglycerides in blood | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-03-22 | — | — | EP | disclosed |
| EP-1626963-A1 | SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-02-22 | — | — | EP | disclosed |
| US-20060020010-A1 | Substituted pyrazoline compounds, their preparation and use as medicaments | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2006-01-26 | — | — | US | disclosed |
| WO-2005077911-A1 | SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2005-08-25 | — | — | WO | disclosed |
| WO-2005077909-A1 | SUBSTITUTED PYRAZOLINE COMPOUNDS FOR REDUCING TRIGLYCERIDES IN BLOOD | LABORATORIOS DR. ESTEVE S.A. (ES) | 2005-08-25 | — | — | WO | disclosed |
| US-6204220-B1 | AS HERBICIDES FOR CONTROLLING UNWANTED VEGETATION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2001-03-20 | — | — | US | disclosed |
| EP-0387058-A1 | Process for preparing benzylpyruvic acids and esters | MERCK & CO. INC. (US) | 1990-09-12 | — | — | EP | disclosed |
| US-4956490-A | Process for preparing benzylpyruvic acids and esters | MERCK & CO., INC. (US) | 1990-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020010-A1 | Substituted pyrazoline compounds, their preparation and use as medicaments | PIR, SYMPK, P2RX5 | CYP1A2 110/4885MAOB 798/4885HDAC2 715/4885 |
| US-20060189658-A1 | Substituted pyrazoline compounds, their preparation and use as medicaments | PIR, SYMPK, P2RX5 | CYP1A2 110/4885MAOB 798/4885HDAC2 715/4885 |
| US-20110160459-A1 | 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLINES AS CANNABINOID CB1 RECEPTOR AGONISTS | CNR1, CNR2, HTR5A | CYP1A2 273/4885MAOB 1112/4885HDAC2 2169/4885 |
| US-20110160181-A1 | SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | PIR, SYMPK, P2RX5 | CYP1A2 110/4885MAOB 798/4885HDAC2 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.